;PMID: 2504935
;source_file_2873.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..183] = [t:45..183]
;2)section:[e:187..242] = [t:187..242]
;3)section:[e:246..302] = [t:246..302]
;4)sentence:[e:306..546] = [t:306..546]
;5)sentence:[e:547..780] = [t:547..780]
;6)sentence:[e:781..848] = [t:781..848]
;7)sentence:[e:849..1071] = [t:849..1071]
;8)sentence:[e:1072..1138] = [t:1072..1138]
;9)sentence:[e:1140..1348] = [t:1140..1348]
;10)section:[e:1352..1396] = [t:1352..1396]

;section 0 Span:0..39
;J Neurosci Res.  1989 Jul;23(3):274-81.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..10] Neurosci) (NNP:[11..14] Res) (.:[14..15] .)
        (CD:[17..21] 1989) (CC:[22..29] Jul;23-LRB-) (CD:[29..30] 3)
        (-RRB-:[30..31] -RRB-) (CD:[31..35] :274) (::[35..36] -)
        (CD:[36..38] 81) (.:[38..39] .)))

;sentence 1 Span:45..183
;Induction of morphological differentiation of human neuroblastoma cells is 
;accompanied by induction of tissue-type plasminogen activator.
;[97..110]:malignancy-type:"neuroblastoma"
;[149..182]:gene-protein:"tissue-type plasminogen activator"
(SENT
  (S-HLN
    (NP-SBJ-1
      (NP (NN:[45..54] Induction))
      (PP (IN:[55..57] of)
        (NP
          (NP (JJ:[58..71] morphological) (NN:[72..87] differentiation))
          (PP (IN:[88..90] of)
            (NP (JJ:[91..96] human) (NN:[97..110] neuroblastoma)
                (NNS:[111..116] cells))))))
    (VP (VBZ:[117..119] is)
      (VP (VBN:[121..132] accompanied)
        (NP-1 (-NONE-:[132..132] *))
        (PP (IN:[133..135] by)
          (NP-LGS
            (NP (NN:[136..145] induction))
            (PP (IN:[146..148] of)
              (NP
                (NML (NN:[149..155] tissue) (HYPH:[155..156] -)
                     (NN:[156..160] type))
                (NN:[161..172] plasminogen) (NN:[173..182] activator)))))))
    (.:[182..183] .)))

;section 2 Span:187..242
;Neuman T, Stephens RW, Salonen EM, Timmusk T, Vaheri A.
(SEC
  (FRAG (NNP:[187..193] Neuman) (NNP:[194..195] T) (,:[195..196] ,)
        (NNP:[197..205] Stephens) (NNP:[206..208] RW) (,:[208..209] ,)
        (NNP:[210..217] Salonen) (NN:[218..220] EM) (,:[220..221] ,)
        (NNP:[222..229] Timmusk) (NNP:[230..231] T) (,:[231..232] ,)
        (NNP:[233..239] Vaheri) (NNP:[240..241] A) (.:[241..242] .)))

;section 3 Span:246..302
;Department of Virology, University of Helsinki, Finland.
(SEC
  (FRAG (NNP:[246..256] Department) (IN:[257..259] of) (NNP:[260..268] Virology)
        (,:[268..269] ,) (NNP:[270..280] University) (IN:[281..283] of)
        (NNP:[284..292] Helsinki) (,:[292..293] ,) (NNP:[294..301] Finland)
        (.:[301..302] .)))

;sentence 4 Span:306..546
;Human SH-SY5Y neuroblastoma cells treated with retinoic acid, 
;12-O-tetradecanoyl-phorbol-13-acetate (TPA) or nerve growth factor 
;differentiated morphologically to neuronlike cells with increased amounts of 
;neurofilament protein and mRNA.
;[320..333]:malignancy-type:"neuroblastoma"
;[416..435]:gene-protein:"nerve growth factor"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[306..311] Human) (NN:[312..319] SH-SY5Y)
          (NN:[320..333] neuroblastoma) (NNS:[334..339] cells))
      (VP (VBN:[340..347] treated)
        (NP (-NONE-:[347..347] *))
        (PP (IN:[348..352] with)
          (NP
            (NP (JJ:[353..361] retinoic) (NN:[362..366] acid))
            (NP (,:[366..367] ,)
              (NP (NN:[369..406] 12-O-tetradecanoyl-phorbol-13-acetate))
              (NP (-LRB-:[407..408] -LRB-) (NN:[408..411] TPA)
                  (-RRB-:[411..412] -RRB-)))
            (CC:[413..415] or)
            (NP (NN:[416..421] nerve) (NN:[422..428] growth)
                (NN:[429..435] factor))))))
    (VP (VBD:[437..451] differentiated)
      (ADVP (RB:[452..467] morphologically))
      (PP (TO:[468..470] to)
        (NP
          (NP (JJ:[471..481] neuronlike) (NNS:[482..487] cells))
          (PP (IN:[488..492] with)
            (NP
              (NP (VBN:[493..502] increased) (NNS:[503..510] amounts))
              (PP (IN:[511..513] of)
                (NP
                  (NP (NN:[515..528] neurofilament) (NN:[529..536] protein))
                  (CC:[537..540] and)
                  (NP (NN:[541..545] mRNA)))))))))
    (.:[545..546] .)))

;sentence 5 Span:547..780
;All three effectors induced an increase in the  amount of relative molecular
;weight (Mr) 70,000 tissue-type plasminogen  activator (t-PA) and its mRNA, as
;determined by immunocapture, enzyme activity,  and Northern blotting
;analyses.
;[643..677]:gene-protein:"tissue-type plasminogen  activator"
;[679..683]:gene-protein:"t-PA"
(SENT
  (S
    (NP-SBJ (DT:[547..550] All) (CD:[551..556] three) (NNS:[557..566] effectors))
    (VP (VBD:[567..574] induced)
      (NP
        (NP (DT:[575..577] an) (NN:[578..586] increase))
        (PP (IN:[587..589] in)
          (NP
            (NP (DT:[590..593] the) (NN:[595..601] amount))
            (PP (IN:[602..604] of)
              (NP
                (NP (JJ:[605..613] relative) (JJ:[614..623] molecular)
                    (NN:[624..630] weight)
                  (PRN (-LRB-:[631..632] -LRB-)
                    (NP (NN:[632..634] Mr))
                    (-RRB-:[634..635] -RRB-))
                  (CD:[636..642] 70,000)
                  (NML
                    (NML
                      (NML (NN:[643..649] tissue) (HYPH:[649..650] -)
                           (NN:[650..654] type))
                      (NN:[655..666] plasminogen) (NN:[668..677] activator))
                    (NML (-LRB-:[678..679] -LRB-) (NN:[679..683] t-PA)
                         (-RRB-:[683..684] -RRB-))))
                (CC:[685..688] and)
                (NP (PRP$:[689..692] its) (NN:[693..697] mRNA)))))))
      (,:[697..698] ,)
      (SBAR-ADV (IN:[699..701] as)
        (S
          (NP-SBJ-1 (-NONE-:[701..701] *))
          (VP (VBN:[702..712] determined)
            (NP-1 (-NONE-:[712..712] *))
            (PP-MNR (IN:[713..715] by)
              (NP
                (NP (NN:[716..729] immunocapture))
                (,:[729..730] ,)
                (NP (NN:[731..737] enzyme) (NN:[738..746] activity))
                (,:[746..747] ,) (CC:[749..752] and)
                (NP (JJ:[753..761] Northern) (NN:[762..770] blotting)
                    (NNS:[771..779] analyses))))))))
    (.:[779..780] .)))

;sentence 6 Span:781..848
;About 90% of the t-PA activity was secreted to  the culture medium.
;[798..802]:gene-protein:"t-PA"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (QP (RB:[781..786] About) (CD:[787..789] 90))
        (NN:[789..790] %))
      (PP (IN:[791..793] of)
        (NP (DT:[794..797] the) (NN:[798..802] t-PA) (NN:[803..811] activity))))
    (VP (VBD:[812..815] was)
      (VP (VBN:[816..824] secreted)
        (NP-1 (-NONE-:[824..824] *))
        (PP (TO:[825..827] to)
          (NP (DT:[829..832] the) (NN:[833..840] culture) (NN:[841..847] medium)))))
    (.:[847..848] .)))

;sentence 7 Span:849..1071
;In contrast, of the three effectors studied, only TPA  induced transcription
;of the proto-oncogene c-fos, studied as a control gene  responsive to various
;stimuli, and induced a rapid increase in urokinase-type PA  (u-PA).
;[948..953]:gene-rna:"c-fos"
;[1045..1062]:gene-protein:"urokinase-type PA"
;[1065..1069]:gene-protein:"u-PA"
(SENT
  (S
    (PP (IN:[849..851] In)
      (NP (NN:[852..860] contrast)))
    (,:[860..861] ,)
    (PP-1 (IN:[862..864] of)
      (NP
        (NP (DT:[865..868] the) (CD:[869..874] three) (NNS:[875..884] effectors))
        (VP (VBN:[885..892] studied)
          (NP (-NONE-:[892..892] *)))))
    (,:[892..893] ,)
    (NP-SBJ (RB:[894..898] only) (NN:[899..902] TPA)
      (PP-TPC-1 (-NONE-:[902..902] *T*)))
    (VP
      (VP (VBD:[904..911] induced)
        (NP
          (NP (NN:[912..925] transcription))
          (PP (IN:[926..928] of)
            (NP
              (NP (DT:[929..932] the)
                (NML (AFX:[933..938] proto) (HYPH:[938..939] -)
                     (NN:[939..947] oncogene))
                (NN:[948..953] c-fos))
              (,:[953..954] ,)
              (VP (VBN:[955..962] studied)
                (NP (-NONE-:[962..962] *))
                (PP (IN:[963..965] as)
                  (NP
                    (NP (DT:[966..967] a) (NN:[968..975] control)
                        (NN:[976..980] gene))
                    (ADJP (JJ:[982..992] responsive)
                      (PP (TO:[993..995] to)
                        (NP (JJ:[996..1003] various) (NNS:[1004..1011] stimuli)))))))))))
      (,:[1011..1012] ,) (CC:[1013..1016] and)
      (VP (VBD:[1017..1024] induced)
        (NP
          (NP (DT:[1025..1026] a) (JJ:[1027..1032] rapid)
              (NN:[1033..1041] increase))
          (PP (IN:[1042..1044] in)
            (NP
              (NP
                (NML (NN:[1045..1054] urokinase) (HYPH:[1054..1055] -)
                     (NN:[1055..1059] type))
                (NN:[1060..1062] PA))
              (NP (-LRB-:[1064..1065] -LRB-) (NN:[1065..1069] u-PA)
                  (-RRB-:[1069..1070] -RRB-)))))))
    (.:[1070..1071] .)))

;sentence 8 Span:1072..1138
;Most of the u-PA activity induced by TPA remained cell-associated.
;[1084..1088]:gene-protein:"u-PA"
(SENT
  (S
    (NP-SBJ
      (NP (JJS:[1072..1076] Most))
      (PP (IN:[1077..1079] of)
        (NP
          (NP (DT:[1080..1083] the) (NN:[1084..1088] u-PA)
              (NN:[1089..1097] activity))
          (VP (VBN:[1098..1105] induced)
            (NP (-NONE-:[1105..1105] *))
            (PP (IN:[1106..1108] by)
              (NP-LGS (NN:[1109..1112] TPA)))))))
    (VP (VBD:[1113..1121] remained)
      (ADJP-PRD (NN:[1122..1126] cell) (HYPH:[1126..1127] -)
                (VBN:[1127..1137] associated)))
    (.:[1137..1138] .)))

;sentence 9 Span:1140..1348
;Because induction of differentiation correlated closely with induction of
;t-PA,  and not u-PA, the authors propose that t-PA may have a functional role
;in the  morphological differentiation of neuronal cells.
;[1214..1218]:gene-protein:"t-PA"
;[1229..1233]:gene-protein:"u-PA"
;[1260..1264]:gene-protein:"t-PA"
(SENT
  (S
    (SBAR-PRP (IN:[1140..1147] Because)
      (S
        (NP-SBJ
          (NP (NN:[1148..1157] induction))
          (PP (IN:[1158..1160] of)
            (NP (NN:[1161..1176] differentiation))))
        (VP
          (VP (VBD:[1177..1187] correlated)
            (ADVP (RB:[1188..1195] closely))
            (PP-CLR (IN:[1196..1200] with)
              (NP=1
                (NP (NN:[1201..1210] induction))
                (PP (IN:[1211..1213] of)
                  (NP (NN:[1214..1218] t-PA))))))
          (,:[1218..1219] ,) (CC:[1221..1224] and)
          (VP (RB:[1225..1228] not)
            (NP=1 (NN:[1229..1233] u-PA))))))
    (,:[1233..1234] ,)
    (NP-SBJ (DT:[1235..1238] the) (NNS:[1239..1246] authors))
    (VP (VBP:[1247..1254] propose)
      (SBAR (IN:[1255..1259] that)
        (S
          (NP-SBJ (NN:[1260..1264] t-PA))
          (VP (MD:[1265..1268] may)
            (VP (VB:[1269..1273] have)
              (NP (DT:[1274..1275] a) (JJ:[1276..1286] functional)
                  (NN:[1287..1291] role))
              (PP (IN:[1292..1294] in)
                (NP
                  (NP (DT:[1295..1298] the) (JJ:[1300..1313] morphological)
                      (NN:[1314..1329] differentiation))
                  (PP (IN:[1330..1332] of)
                    (NP (JJ:[1333..1341] neuronal) (NNS:[1342..1347] cells))))))))))
    (.:[1347..1348] .)))

;section 10 Span:1352..1396
;PMID: 2504935 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1352..1356] PMID) (::[1356..1357] :) (CD:[1358..1365] 2504935)
        (NN:[1366..1367] -LSB-) (NNP:[1367..1373] PubMed) (::[1374..1375] -)
        (NN:[1376..1383] indexed) (IN:[1384..1387] for)
        (NNP:[1388..1396] MEDLINE-RSB-)))
